Cabozantinib combination therapy for the treatment of solid tumors

Background: Cabozantinib monotherapy is approved for the treatment of several types of solid tumors. Investigation into the use of cabozantinib combined with other therapies is increasing. To understand the evidence in this area, we performed a systematic review of cabozantinib combination therapy f...

Full description

Bibliographic Details
Authors: Castellano, Daniel|||0000-0002-9106-0687, Apolo, Andrea B., Porta, Camillo, Capdevila Castillón, Jaume|||0000-0003-0718-8619, Viteri, Santiago|||0000-0002-7572-1123, Rodríguez Antona, Cristina|||0000-0001-8750-7338, Martin, Lidia, Maroto Rey, Pablo|||0000-0002-0030-0412
Format: article
Publication Date:2022
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:277671
Online Access:https://ddd.uab.cat/record/277671
https://dx.doi.org/urn:doi:10.1177/17588359221108691
Access Level:Open access
Keyword:Cabozantinib
Non-small-cell lung cancer
Renal cell carcinoma
Solid tumor
Tyrosine kinase inhibitor
Vascular endothelial growth factor
id ES_09d2d42530cbe7fad3979fe0ee348cd1
oai_identifier_str oai:ddd.uab.cat:277671
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cabozantinib combination therapy for the treatment of solid tumorsa systematic reviewCastellano, Daniel|||0000-0002-9106-0687Apolo, Andrea B.Porta, CamilloCapdevila Castillón, Jaume|||0000-0003-0718-8619Viteri, Santiago|||0000-0002-7572-1123Rodríguez Antona, Cristina|||0000-0001-8750-7338Martin, LidiaMaroto Rey, Pablo|||0000-0002-0030-0412CabozantinibNon-small-cell lung cancerRenal cell carcinomaSolid tumorTyrosine kinase inhibitorVascular endothelial growth factorBackground: Cabozantinib monotherapy is approved for the treatment of several types of solid tumors. Investigation into the use of cabozantinib combined with other therapies is increasing. To understand the evidence in this area, we performed a systematic review of cabozantinib combination therapy for the treatment of solid tumors in adults. Methods: This study was designed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses, and the protocol was registered with PROSPERO (CRD42020144680). On 9 October 2020, we searched for clinical trials and observational studies of cabozantinib as part of a combination therapy for solid tumors using Embase, MEDLINE, and Cochrane databases, and by screening relevant congress abstracts. Eligible studies reported clinical or safety outcomes, or biomarker data. Randomized and observational studies with a sample size of fewer than 25 and studies of cabozantinib monotherapy were excluded. For each study, quality was assessed using National Institute for Health and Care Excellence methodology, and the study characteristics were described qualitatively. This study was funded by Ipsen. Results: Of 2421 citations identified, 32 articles were included (6 with results from randomized studies, 24 with results from non-randomized phase I or II studies, and 2 with results from both). The most commonly studied tumor types were metastatic urothelial carcinoma/genitourinary tumors and castration-resistant prostate cancer (CRPC). Findings from randomized studies suggested that cabozantinib combined with other therapies may lead to better progression-free survival than some current standards of care in renal cell carcinoma, CRPC, and non-small-cell lung cancer. The most common adverse events were hypertension, diarrhea, and fatigue. Conclusion: This review demonstrates the promising efficacy outcomes of cabozantinib combined with other therapies, and a safety profile similar to cabozantinib alone. However, the findings are limited by the fact that most of the identified studies were reported as congress abstracts only. More evidence from randomized trials is needed to explore cabozantinib as a combination therapy further. 22022-01-0120222022-01-01Article de revisióhttp://purl.org/coar/resource_type/c_dcae04bcVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/277671https://dx.doi.org/urn:doi:10.1177/17588359221108691reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2776712026-06-06T12:50:31Z
dc.title.none.fl_str_mv Cabozantinib combination therapy for the treatment of solid tumors
a systematic review
title Cabozantinib combination therapy for the treatment of solid tumors
spellingShingle Cabozantinib combination therapy for the treatment of solid tumors
Castellano, Daniel|||0000-0002-9106-0687
Cabozantinib
Non-small-cell lung cancer
Renal cell carcinoma
Solid tumor
Tyrosine kinase inhibitor
Vascular endothelial growth factor
title_short Cabozantinib combination therapy for the treatment of solid tumors
title_full Cabozantinib combination therapy for the treatment of solid tumors
title_fullStr Cabozantinib combination therapy for the treatment of solid tumors
title_full_unstemmed Cabozantinib combination therapy for the treatment of solid tumors
title_sort Cabozantinib combination therapy for the treatment of solid tumors
dc.creator.none.fl_str_mv Castellano, Daniel|||0000-0002-9106-0687
Apolo, Andrea B.
Porta, Camillo
Capdevila Castillón, Jaume|||0000-0003-0718-8619
Viteri, Santiago|||0000-0002-7572-1123
Rodríguez Antona, Cristina|||0000-0001-8750-7338
Martin, Lidia
Maroto Rey, Pablo|||0000-0002-0030-0412
author Castellano, Daniel|||0000-0002-9106-0687
author_facet Castellano, Daniel|||0000-0002-9106-0687
Apolo, Andrea B.
Porta, Camillo
Capdevila Castillón, Jaume|||0000-0003-0718-8619
Viteri, Santiago|||0000-0002-7572-1123
Rodríguez Antona, Cristina|||0000-0001-8750-7338
Martin, Lidia
Maroto Rey, Pablo|||0000-0002-0030-0412
author_role author
author2 Apolo, Andrea B.
Porta, Camillo
Capdevila Castillón, Jaume|||0000-0003-0718-8619
Viteri, Santiago|||0000-0002-7572-1123
Rodríguez Antona, Cristina|||0000-0001-8750-7338
Martin, Lidia
Maroto Rey, Pablo|||0000-0002-0030-0412
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Cabozantinib
Non-small-cell lung cancer
Renal cell carcinoma
Solid tumor
Tyrosine kinase inhibitor
Vascular endothelial growth factor
topic Cabozantinib
Non-small-cell lung cancer
Renal cell carcinoma
Solid tumor
Tyrosine kinase inhibitor
Vascular endothelial growth factor
description Background: Cabozantinib monotherapy is approved for the treatment of several types of solid tumors. Investigation into the use of cabozantinib combined with other therapies is increasing. To understand the evidence in this area, we performed a systematic review of cabozantinib combination therapy for the treatment of solid tumors in adults. Methods: This study was designed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses, and the protocol was registered with PROSPERO (CRD42020144680). On 9 October 2020, we searched for clinical trials and observational studies of cabozantinib as part of a combination therapy for solid tumors using Embase, MEDLINE, and Cochrane databases, and by screening relevant congress abstracts. Eligible studies reported clinical or safety outcomes, or biomarker data. Randomized and observational studies with a sample size of fewer than 25 and studies of cabozantinib monotherapy were excluded. For each study, quality was assessed using National Institute for Health and Care Excellence methodology, and the study characteristics were described qualitatively. This study was funded by Ipsen. Results: Of 2421 citations identified, 32 articles were included (6 with results from randomized studies, 24 with results from non-randomized phase I or II studies, and 2 with results from both). The most commonly studied tumor types were metastatic urothelial carcinoma/genitourinary tumors and castration-resistant prostate cancer (CRPC). Findings from randomized studies suggested that cabozantinib combined with other therapies may lead to better progression-free survival than some current standards of care in renal cell carcinoma, CRPC, and non-small-cell lung cancer. The most common adverse events were hypertension, diarrhea, and fatigue. Conclusion: This review demonstrates the promising efficacy outcomes of cabozantinib combined with other therapies, and a safety profile similar to cabozantinib alone. However, the findings are limited by the fact that most of the identified studies were reported as congress abstracts only. More evidence from randomized trials is needed to explore cabozantinib as a combination therapy further.
publishDate 2022
dc.date.none.fl_str_mv 2
2022-01-01
2022
2022-01-01
dc.type.none.fl_str_mv Article de revisió
http://purl.org/coar/resource_type/c_dcae04bc
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/277671
https://dx.doi.org/urn:doi:10.1177/17588359221108691
url https://ddd.uab.cat/record/277671
https://dx.doi.org/urn:doi:10.1177/17588359221108691
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403128344870912
score 15.812429

Similar Items